摘要：Editorial Office of Chinese Journal of Lung Cancer,[Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutati

参考文献：

[1] Editorial Office of Chinese Journal of Lung Cancer,[Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutation].[J] .Zhongguo Fei Ai Za Zhi, 2023, 26: 416-428.

[2] 《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》http://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=de66e92b7edd4056ac41c0c4d3c011f3.pdf

[3] Mazieres Julien, Vioix Helene, Pfeiffer Boris M, et al. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clin Lung Cancer, 2023, 24: 483-497.

[4] 中华医学会病理学分会, 国家病理质控中心, 中华医学会肿瘤学分会肺癌学组, 等. 非小细胞肺癌MET临床检测中国专家共识 [J] . 中华病理学杂志, 2022, 51(11) : 1094-1103.

[5] Wolf Jürgen, Hochmair Maximilian, Han Ji-Youn, et al. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol, 2024, 25: 1357-1370.

[6] Yi-Long Wu, et al. Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study. 2022 ESMO AISA, 388P.

[7] Fujino T, Kobayashi Y, Suda K, et al. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. J Thorac Oncol. 2019;14(10):1753-1765.

[8] Offin Michael, Luo Jia, Guo Robin, et al. CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. JCO Precis Oncol, 2020, 4: undefined.

[9] Grande Enrique, Giovannini Monica, Marriere Eddie, et al. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. Br J Clin Pharmacol, 2021, 87: 2867-2878.

[10] Pan Kelsey, Concannon Kyle, Li Jing, et al. Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer. Nat Rev Clin Oncol, 2023, 20: 716-732.

[11] Paik Paul K, Goyal Ravi K, Cai Beilei, et al. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol, 2023, 19: 217-228.

[12] Wolf Jürgen, Seto Takashi ,Han Ji-Youn, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.[J] .N Engl J Med, 2020, 383: 944-957.

[13] Mazieres Julien, Paik Paul K, Garassino Marina C, et al. Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.[J] .JAMA Oncol, 2023, 9: 1260-1266.

[14] Jin-Ji Yang, et al. Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations. 2023 ESMO, 1379P.

[15] Terufumi, Kato,James Chih-Hsin, Yang,Myung-Ju, Ahn et al. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.[J] .Br J Cancer, 2024, 130: 0.

[16] Yongfeng Yu, Jianya Zhou, Xingya Li, et al. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial.[J] .EClinicalMedicine, 2023, 59: 0.

[17] Shun Lu, Jian Fang, Xingya Li, et al. Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations.[J] .JTO Clin Res Rep, 2022, 3: 0.

[18] Xinhui Chen, Xiaoming Cui, Nathalie Pognan, et al. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.[J] .Br J Clin Pharmacol, 2021, 88: 0.

[19] 简明处方：https://www.medlive.cn/recommond.php?kyprojectid=1_002094401_1&hash=DaGO1J

撰写：Cynthia

审校：Felicia

排版：Faline

执行：Faline

来源：医脉通肿瘤科